Arcturus Therapeutics Holdings Inc.
ARCT · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $138 | $158 | $206 | $12 |
| % Growth | -12.3% | -23.3% | 1,564.8% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $138 | $158 | $206 | $12 |
| % Margin | 100% | 100% | 100% | 100% |
| R&D Expenses | $195 | $192 | $148 | $174 |
| G&A Expenses | $53 | $53 | $46 | $41 |
| SG&A Expenses | $53 | $53 | $46 | $41 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$14 | -$9 | -$0 | $0 |
| Operating Expenses | $234 | $236 | $194 | $215 |
| Operating Income | -$96 | -$78 | $12 | -$203 |
| % Margin | -69.1% | -49.6% | 5.9% | -1,641.3% |
| Other Income/Exp. Net | $15 | $50 | -$2 | -$1 |
| Pre-Tax Income | -$81 | -$28 | $11 | -$204 |
| Tax Expense | -$0 | $2 | $1 | $0 |
| Net Income | -$81 | -$30 | $9 | -$204 |
| % Margin | -58.5% | -18.8% | 4.5% | -1,648% |
| EPS | -3 | -1.12 | 0.35 | -7.74 |
| % Growth | -167.9% | -420% | 104.5% | – |
| EPS Diluted | -3 | -1.12 | 0.35 | -7.74 |
| Weighted Avg Shares Out | 27 | 27 | 26 | 26 |
| Weighted Avg Shares Out Dil | 27 | 27 | 27 | 26 |
| Supplemental Information | – | – | – | – |
| Interest Income | $15 | $17 | $3 | $1 |
| Interest Expense | $0 | $1 | $3 | $3 |
| Depreciation & Amortization | $4 | $3 | $2 | $1 |
| EBITDA | -$77 | -$24 | $14 | -$202 |
| % Margin | -55.9% | -15.3% | 6.7% | -1,631.7% |